A Comprehensive Monograph on Azelaic Acid (DB00548): Mechanisms, Clinical Utility, and Regulatory Landscape

1.0 Executive Summary

Azelaic acid is a naturally occurring, saturated nine-carbon dicarboxylic acid that has emerged as a uniquely versatile and indispensable therapeutic agent in modern dermatology. Initially identified for its effects on skin pigmentation, its clinical utility has expanded significantly, driven by a growing understanding of its pleiotropic pharmacological activities. This monograph provides an exhaustive analysis of Azelaic acid, synthesizing data from pharmacological databases, clinical trials, and global regulatory documents to present a definitive, evidence-based report on its properties, mechanisms, and clinical applications.

The primary FDA-approved indications for Azelaic acid are the topical treatment of mild-to-moderate inflammatory acne vulgaris and the inflammatory papules and pustules of mild-to-moderate rosacea. Its efficacy in these conditions is underpinned by a multifaceted mechanism of action that simultaneously targets the core pathophysiological pillars of these diseases. Azelaic acid exerts potent anti-infective effects against key cutaneous microorganisms such as Propionibacterium acnes, notable for the absence of observed bacterial resistance. It possesses significant anti-inflammatory properties, scavenging reactive oxygen species and modulating critical inflammatory pathways, including the kallikrein-5/cathelicidin cascade central to rosacea. Furthermore, its anti-keratinizing activity normalizes follicular differentiation, preventing the formation of comedones in acne, while its inhibition of tyrosinase and selective cytotoxicity towards hyperactive melanocytes make it an effective agent for a growing number of off-label applications in disorders of hyperpigmentation, such as melasma and post-inflammatory hyperpigmentation.

The pharmacokinetic profile of Azelaic acid is ideally suited for a topical dermatological agent. Its percutaneous absorption is slow and minimal (approximately 4%), establishing a "topical reservoir" within the epidermis and dermis. This allows for a prolonged local therapeutic effect, enabling a convenient twice-daily dosing regimen, while ensuring negligible systemic exposure. The small fraction of the drug that is absorbed is rapidly metabolized via standard fatty acid pathways or excreted unchanged, resulting in an exceptionally favorable safety profile. Adverse events are almost exclusively localized to the application site, are typically mild and transient, and include burning, stinging, and pruritus. Systemic side effects and clinically significant drug-drug interactions are not a concern with topical administration. Its safety in pregnancy (Pregnancy Category B) and lactation further solidifies its position as a first-line or alternative therapy in sensitive patient populations.

A fascinating aspect of Azelaic acid is the profound divergence in its global regulatory status. In the United States, it is strictly regulated as a prescription-only medication. In contrast, the European Union classifies it as a cosmetic ingredient with no concentration restrictions, allowing for widespread over-the-counter access to high-strength formulations. Australia occupies a middle ground with a tiered, pharmacy-led model. This regulatory disparity has significant implications for patient access, clinical practice, and the commercial landscape. This report concludes that Azelaic acid is a cornerstone therapeutic agent in dermatology, distinguished by its multi-modal efficacy, exceptional safety, and a continually expanding clinical role.

2.0 Identification and Physicochemical Properties

2.1 Chemical Identity

Azelaic acid is a small molecule classified as a saturated dicarboxylic acid.[1] Its fundamental chemical identity is well-established across multiple chemical and pharmacological databases.

• Systematic (IUPAC) Name: The formal International Union of Pure and Applied Chemistry (IUPAC) name for the molecule is nonanedioic acid.[2]
• Common Chemical Names: It is also referred to as 1,7-heptanedicarboxylic acid, a name that describes its structure as a seven-carbon (heptane) chain with carboxylic acid groups at each end.[3]
• CAS Number: The Chemical Abstracts Service (CAS) Registry Number, a unique numerical identifier, is 123-99-9.[2]
• DrugBank ID: The unique accession number in the DrugBank database is DB00548.[1]
• Molecular Formula: The empirical formula is .[2]
• Molecular Weight: The molecular weight of the compound is 188.22 g/mol.[2]
• Structure: Structurally, it is a straight-chain, saturated aliphatic dicarboxylic acid with a total of nine carbon atoms.[1] The presence of a carboxyl group ( ) at both ends of the nine-carbon chain is the defining feature of its structure and is responsible for its chemical properties and biological activity.

2.2 Synonyms and Nomenclature

To facilitate comprehensive literature review and product identification, a variety of synonyms and brand names are used to refer to Azelaic acid.

• Chemical Synonyms: In historical and chemical literature, it may be referred to by several other names, including Anchoic acid, Lepargylic acid, and 1,9-nonanedioic acid.[2]
• Common Brand Names (Pharmaceutical): Prescription formulations are marketed globally under several key brand names. The most prominent in North America and Europe are Azelex® and Finacea®.[1] Skinoren® is another major brand, particularly in Europe, Australia, and other international markets.[9] Finevin® is also a recognized brand name.[7]
• Common Brand Names (Cosmetic/Over-the-Counter): Due to its varied regulatory status, numerous non-prescription products are available. Notable examples include The Ordinary Azelaic Acid Suspension 10%, Hascoderm lipożel (Poland), and Azclear (Australia).[9] A more exhaustive list of international brands is presented in Section 9.4.

2.3 Natural Occurrence and Endogenous Production

A key characteristic of Azelaic acid is that it is not a synthetic xenobiotic but a naturally occurring biological molecule, which has profound implications for its safety and tolerability.

• Dietary Sources: It is a natural constituent of several whole grain cereals, including wheat, rye, and barley.[1] Dietary intake is a primary source of baseline endogenous levels in humans.
• Microbial Production: Azelaic acid is produced as a metabolic byproduct of the lipophilic yeast Malassezia furfur (historically known as Pityrosporum ovale). This yeast is a commensal microorganism that is part of the normal human skin microbiome.[1] The observation that skin depigmentation could occur in areas of Pityrosporum overgrowth (pityriasis versicolor) was one of the initial clues that led to the investigation of dicarboxylic acids as tyrosinase inhibitors.[12]
• Endogenous Formation: The human body can also produce Azelaic acid endogenously. It is formed from the metabolism of longer-chain dicarboxylic acids, the ω-oxidation of monocarboxylic acids like oleic acid, and is also identified as a metabolite in microorganisms such as Escherichia coli.[2]

The presence of Azelaic acid as a natural dietary constituent, a metabolic byproduct of commensal skin flora, and an endogenous metabolite provides a strong biological basis for its exceptional tolerability. The human body possesses pre-existing metabolic pathways, such as mitochondrial β-oxidation, for its catabolism.[1] This inherent familiarity prevents the systemic accumulation of a novel xenobiotic and likely mitigates the risk of systemic toxicity and idiosyncratic adverse reactions that can be associated with entirely synthetic compounds. This biological context is fundamental to understanding its favorable position in the dermatological therapeutic armamentarium.

3.0 Comprehensive Mechanism of Action

The clinical success of Azelaic acid across a spectrum of seemingly disparate dermatological conditions—from acne and rosacea to hyperpigmentation—is not attributable to a single mode of action. Instead, its efficacy is rooted in its pleiotropic nature, allowing it to simultaneously modulate multiple distinct pathophysiological pathways. This multi-pronged mechanism makes it a uniquely versatile single agent.

3.1 Anti-Infective Properties

Azelaic acid exhibits significant antimicrobial activity against key microorganisms implicated in the pathogenesis of acne vulgaris.

• Target Microorganisms: It demonstrates bacteriostatic properties against a variety of aerobic and anaerobic microorganisms. At the concentrations achieved with topical therapy, it is bactericidal against the anaerobic bacterium Propionibacterium acnes (now referred to as Cutibacterium acnes) and the aerobic bacterium Staphylococcus epidermidis, both of which are found in elevated numbers on acne-prone skin.[1] It also shows demonstrable activity against Staphylococcus aureus.[12]
• Primary Mechanism: The principal antimicrobial mechanism is the inhibition of microbial cellular protein synthesis.[1] Even at relatively low concentrations (313μM), Azelaic acid has been shown to reduce microbial protein synthesis by over fifty percent.[12] Much higher concentrations are required to inhibit DNA and RNA replication to a similar degree, indicating that protein synthesis is the primary target.[12]
• Secondary Mechanisms: Beyond inhibiting protein synthesis, Azelaic acid disrupts the bacterial intracellular environment through several complementary actions. It is actively transported into P. acnes cells, where it can achieve intracellular concentrations over 90 times greater than that of the surrounding tissue environment.[12] This high intracellular concentration is thought to disable the bacterium's ability to maintain the necessary pH difference across its cell membrane. This disruption impairs the efficiency of respiratory metabolism and renders the cell more susceptible to changes in environmental pH.[6] In anaerobic bacteria like P. acnes, Azelaic acid also directly impedes glycolysis, a critical energy-producing pathway.[1]
• Lack of Resistance: A paramount clinical advantage of Azelaic acid is the absence of observed bacterial resistance. To date, no resistant strains of P. acnes have been identified in either in vitro or in vivo studies.[12] This contrasts sharply with the growing problem of resistance to topical and oral antibiotics commonly used in acne management, positioning Azelaic acid as a durable and reliable long-term therapeutic option.

3.2 Anti-Inflammatory Effects

Azelaic acid exerts potent anti-inflammatory effects that are central to its efficacy in treating both inflammatory acne and rosacea.

• ROS Scavenging: It functions as a direct antioxidant, scavenging reactive oxygen species (ROS) that contribute to inflammation and tissue damage. It is particularly effective against the highly toxic free hydroxyl radical (•OH).[8]
• Inhibition of Neutrophil Activity: A key source of ROS in inflammatory skin conditions is the oxidative burst from neutrophils. Azelaic acid directly inhibits the production of ROS by these inflammatory cells, thereby reducing oxidative stress at the site of inflammation.[8]
• Cytokine Modulation: The anti-inflammatory action extends to the molecular signaling level. Azelaic acid reduces the production of pro-inflammatory cytokines.[13] It achieves this by disrupting the pro-inflammatory mitogen-activated protein kinase (MAPK) signaling pathway. This disruption leads to the downregulation of the critical transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which in turn causes a decreased expression of key pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β).[6]
• Rosacea-Specific Pathway: In the specific context of rosacea, Azelaic acid targets a key pathogenic pathway. It has been shown to inhibit kallikrein-5, a serine protease that is overexpressed in the skin of rosacea patients.[6] Kallikrein-5 is responsible for cleaving the antimicrobial peptide LL-37 from its precursor, cathelicidin. The resulting active LL-37 fragments are potent drivers of the inflammation, vasodilation, and angiogenesis characteristic of rosacea. By inhibiting kallikrein-5, Azelaic acid leads to decreased gene expression of cathelicidin and reduced levels of pro-inflammatory LL-37, directly intervening in the core inflammatory cascade of the disease.[6]

3.3 Anti-Keratinizing and Comedolytic Activity

A fundamental process in the development of acne is follicular hyperkeratinization, which leads to the formation of microcomedones. Azelaic acid directly counteracts this process.

• Normalization of Keratinization: The drug normalizes the process of keratinization within the hair follicle, exerting a potent anticomedonal effect.[1] This action addresses the initial step in acne lesion formation and is effective against both non-inflamed (comedones) and inflamed lesions.
• Mechanism: The anti-keratinizing effect is achieved through several actions on epidermal differentiation. It reduces the thickness of the stratum corneum, the outermost layer of the skin.[1] This is thought to be mediated by its ability to decrease the synthesis, amount, and distribution of filaggrin, a key protein responsible for aggregating keratin filaments into tight bundles within keratinocytes.[1] The reduction in filaggrin leads to a corresponding decrease in the number and size of keratohyalin granules, which are precursors to the cornified envelope of skin cells.[1] This modulation of both the early and final phases of epidermal differentiation prevents the abnormal shedding and cohesion of keratinocytes that block the follicle and form a microcomedo.
• Comedolytic Effect: In addition to preventing the formation of new comedones, Azelaic acid possesses comedolytic properties, meaning it helps in the breakdown and expulsion of existing comedones (both open comedones/blackheads and closed comedones/whiteheads).[13] This dual action—preventing new lesions and helping to clear existing ones—makes it a comprehensive treatment for comedonal acne.

3.4 Inhibition of Melanogenesis

Azelaic acid's ability to modulate melanin production was one of its first recognized properties and forms the basis for its use in treating hyperpigmentary disorders.

• Primary Mechanism: The principal mechanism is the competitive inhibition of tyrosinase, the key, rate-limiting enzyme in the biosynthesis of melanin.[1] By competing with the natural substrate, tyrosine, for the active site of the enzyme, Azelaic acid effectively slows down the entire melanogenesis cascade.
• Synergistic Mechanism: Its inhibitory action is further enhanced by its effect on thioredoxin reductase.[1] The enzyme thioredoxin reductase is responsible for maintaining a pool of reduced thioredoxin in the cell. Reduced thioredoxin, in turn, regulates the activity of tyrosinase through a feedback mechanism.[8] By inhibiting thioredoxin reductase, Azelaic acid indirectly downregulates tyrosinase activity, providing a secondary layer of control over melanin production.
• Selective Cytotoxicity: A remarkable feature of Azelaic acid is its selective effect on melanocytes. It demonstrates a preferential antiproliferative and cytotoxic effect on hyperactive and abnormal melanocytes, such as those found in melasma or malignant melanoma, while having minimal impact on normal, healthy melanocytes.[13] This selectivity is thought to be due to its interference with DNA synthesis (via inhibition of DNA polymerase and thioredoxin reductase) and mitochondrial enzymes of the respiratory chain, processes that are upregulated in highly proliferative or abnormal cells.[13] This allows it to effectively treat areas of hyperpigmentation without causing significant lightening or hypopigmentation of the surrounding normal skin, a common concern with other depigmenting agents like hydroquinone.

3.5 Broad-Spectrum Enzyme Inhibition

The molecular actions of Azelaic acid extend to a range of other enzymes, which contributes to its diverse biological effects.

• Inhibitory Targets: Azelaic acid is a reversible inhibitor of a variety of oxidoreductive enzymes. In addition to tyrosinase and thioredoxin reductase, these targets include mitochondrial enzymes of the respiratory chain, DNA polymerases, and 5-alpha-reductase.[1]
• Clinical Relevance: The inhibition of these enzymes has direct clinical consequences. The inhibition of 5-alpha-reductase, the enzyme that converts testosterone to the more potent androgen dihydrotestosterone (DHT), provides an anti-androgenic and anti-seborrheic effect, which is beneficial in the management of acne.[8] The inhibition of mitochondrial respiration and DNA synthesis underlies its antiproliferative effects on keratinocytes (contributing to its anti-keratinizing action) and its cytotoxic effects on abnormal melanocytes and tumor cells.[9] This broad enzymatic inhibition profile underscores the molecular basis for its pleiotropic activity.

4.0 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of topically applied Azelaic acid is characterized by extensive local penetration with minimal systemic absorption, a combination that maximizes therapeutic efficacy at the target site (the skin) while ensuring a high degree of systemic safety.

4.1 Topical Absorption and Penetration

• Penetration: Following a single topical application, Azelaic acid effectively penetrates the outer layers of the skin. Approximately 3% to 5% of the applied dose penetrates into the stratum corneum, where it can begin to exert its anti-keratinizing effects.[5] Further penetration into the viable skin layers is observed, with up to 10% of the dose being found within the epidermis and dermis, the location of the pilosebaceous units and melanocytes that are the primary targets for its therapeutic action.[5] The formulation vehicle can influence penetration; for instance, liposomal delivery systems have been developed to enhance the drug's penetration through all layers of the skin.[9]
• Systemic Absorption: Despite effective local penetration, systemic absorption of Azelaic acid is minimal. On average, approximately 4% of the topically applied dose is absorbed into the systemic circulation.[1] The degree of absorption can vary slightly depending on the formulation, ranging from around 3% for ointments and emulsions to as high as 8% for gel-based formulations.[9]
• Plasma Levels: This low systemic absorption means that standard topical treatment does not significantly alter the body's natural levels of Azelaic acid. Post-treatment plasma concentrations and daily urinary excretion of the drug are not significantly different from the baseline endogenous levels, which themselves fluctuate based on dietary intake of grains and other sources.[5]

4.2 Systemic Fate and Metabolism

• Metabolism: Azelaic acid that is applied topically undergoes negligible metabolism within the skin itself.[5] The small fraction that is systemically absorbed is handled by the body's natural metabolic pathways for dicarboxylic acids. It undergoes some mitochondrial β-oxidation, a standard process for fatty acid metabolism, which shortens the carbon chain to produce other dicarboxylic acids (such as pimelic acid) and ultimately results in the formation of malonyl-CoA or acetyl-CoA, which can enter the Krebs cycle.[1]
• Distribution: Studies involving systemic (intravenous) administration have shown that Azelaic acid is capable of crossing the blood-brain barrier, with cerebrospinal fluid concentrations reaching approximately 2-5% of the corresponding serum values.[18] However, this finding is primarily of academic interest and is not clinically relevant for standard topical use, where systemic concentrations remain low.
• Excretion: The primary route of elimination for Azelaic acid is renal. It is mainly excreted unchanged in the urine, along with the shorter-chain dicarboxylic acid metabolites produced via β-oxidation.[1]

4.3 Half-Life and Kinetics

A comparison of the drug's half-life following different routes of administration reveals the key principle governing its pharmacokinetics.

• Topical Half-Life: The observed apparent half-life of Azelaic acid following topical dosing is approximately 12 hours.[1]
• Oral Half-Life: In stark contrast, the half-life after oral dosing (which bypasses the skin barrier and leads to rapid systemic absorption) is significantly shorter, at approximately 45 minutes.[1]
• Rate-Limiting Kinetics: The profound difference between the 12-hour topical half-life and the 45-minute oral half-life is a classic demonstration of percutaneous absorption rate-limited kinetics.[1] This means that the slowest step in the entire ADME process is the absorption of the drug through the skin. Once the drug enters the systemic circulation, it is cleared very rapidly. The long 12-hour apparent half-life after topical application does not reflect slow elimination but rather the slow, continuous absorption from the skin depot.

This pharmacokinetic profile creates a "topical reservoir" effect. The slow, rate-limiting absorption from the formulation into the skin establishes a depot of the drug within the epidermis and dermis. This reservoir allows for a prolonged local therapeutic effect at the target site, justifying the convenient twice-daily dosing schedule. Concurrently, this same slow absorption ensures that the systemic circulation is exposed to only a very small, continuous trickle of the drug, which is cleared far more rapidly than it is absorbed. This prevents systemic accumulation and is the fundamental reason for the drug's excellent systemic safety profile and the negligible risk of systemic side effects or drug-drug interactions. This profile represents the ideal pharmacokinetic behavior for a topical dermatological agent, maximizing local efficacy while minimizing systemic risk.

5.0 Clinical Applications and Therapeutic Efficacy

Azelaic acid has established itself as a cornerstone therapy for several common dermatological conditions, with its use supported by robust clinical trial data for its approved indications and a growing body of evidence for its off-label applications.

5.1 FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved Azelaic acid for two primary indications, with specific formulations and strengths tailored to each condition.

• Acne Vulgaris (Mild-to-Moderate): Azelaic acid is approved for the topical treatment of mild-to-moderate inflammatory acne vulgaris.[1] The 20% cream formulation (Azelex®) is specifically indicated for this use.[11] Its efficacy in acne is a direct result of its combined anti-infective, anti-inflammatory, and anti-keratinizing properties. Double-blind clinical trials have demonstrated its effectiveness in reducing both inflammatory lesions (papules and pustules) and non-inflammatory lesions (comedones). One notable comparative trial found that 20% Azelaic acid cream had comparable efficacy to 0.05% tretinoin cream in reducing lesion counts but was associated with significantly fewer local side effects, highlighting its favorable tolerability.[22]
• Rosacea (Mild-to-Moderate Papulopustular): It is also approved for the topical treatment of the inflammatory papules and pustules characteristic of mild-to-moderate rosacea.[6] The 15% gel (Finacea®) and 15% foam (Finacea® Foam) formulations are approved for this indication.[12] Completed Phase 3 clinical trials have confirmed the safety and efficacy of these formulations in reducing the inflammatory lesions of rosacea.[23] It is important to note a specific limitation of use stated in the prescribing information: the efficacy of Azelaic acid for the treatment of persistent erythema (redness) in rosacea in the absence of papules and pustules has not been formally evaluated in pivotal clinical trials.[6] Therefore, it may need to be combined with other modalities to fully address the erythematous component of the disease.[6]

5.2 Off-Label Dermatological Uses

The deep understanding of Azelaic acid's multifaceted mechanisms of action has logically led to its successful application in a variety of off-label conditions, particularly those involving hyperpigmentation and abnormal keratinization.

• Disorders of Hyperpigmentation: Its well-documented ability to inhibit tyrosinase and its selective cytotoxicity towards hyperactive melanocytes make it a valuable tool for treating conditions of excess pigmentation.
• Melasma: It is widely and effectively used off-label for the treatment of melasma (also known as chloasma or "the mask of pregnancy").[6]
• Post-Inflammatory Hyperpigmentation (PIH): Azelaic acid is a particularly useful agent for managing PIH, the dark spots that can remain after inflammatory acne lesions or other skin injuries have healed. This makes it an excellent choice for acne patients concerned with both active lesions and their residual discoloration.[6]
• Solar Lentigines: It is also used to treat solar lentigines, commonly referred to as "age spots" or "liver spots," which are caused by chronic sun exposure.[6]
• Lentigo Maligna: Evidence suggests it has efficacy in treating lentigo maligna, a form of melanoma in situ.[14]
• Other Inflammatory and Keratotic Conditions:
• Plaque Psoriasis: Emerging evidence supports its use in plaque psoriasis. Studies have shown that topical Azelaic acid can be effective in reducing the pruritus (itching), scaling, and hyperkeratosis associated with psoriatic plaques.[6] This application leverages both its anti-inflammatory and anti-keratinizing properties.
• Periorificial Dermatitis: It is also listed among the off-label uses for periorificial dermatitis, an inflammatory rash typically occurring around the mouth, nose, or eyes.[6]

The clinical journey of Azelaic acid exemplifies a positive trend in evidence-based dermatology. Its role has evolved organically from a targeted therapy for acne and rosacea, based on its initial approval studies, to a broad-spectrum agent used for a range of pigmentary and inflammatory dermatoses. This expansion is not arbitrary but is a direct and logical consequence of scientific investigation into its diverse pharmacological mechanisms, with clinicians applying this knowledge to address the pathophysiology of other complex, multifactorial skin conditions.

6.0 Formulations, Dosage, and Administration

The clinical use of Azelaic acid is governed by the availability of several distinct formulations, each with specific approved indications and characteristics. Proper administration is crucial for maximizing efficacy and minimizing local irritation.

6.1 Available Formulations and Strengths

Azelaic acid is available in both prescription-strength and lower-concentration cosmetic formulations.

• Cream 20%: Marketed under brand names such as Azelex® and Skinoren®, the 20% cream is primarily indicated for the treatment of mild-to-moderate acne vulgaris.[1] Based on data from clinical trials regarding local adverse events, the cream formulation appears to be the most tolerable, with a lower incidence of burning, stinging, and pruritus compared to the gel formulation.[6]
• Gel 15%: Marketed as Finacea®, the 15% gel is indicated for the treatment of mild-to-moderate papulopustular rosacea.[9] Pharmacologically, the release of the active drug from the gel vehicle is considered to be superior to that from the cream base, which may contribute to its efficacy in rosacea despite the lower concentration.[25]
• Foam 15%: Also marketed as Finacea® Foam, this formulation is indicated for the same use as the gel: mild-to-moderate papulopustular rosacea.[15] The foam vehicle offers an alternative delivery system that may be preferred by some patients for its cosmetic elegance and ease of application over the entire face.[21]
• Cosmetic Formulations: In regions with less stringent regulations, such as the European Union, Azelaic acid is widely available in over-the-counter cosmetic and cosmeceutical products. These formulations typically contain strengths up to 10%, though higher concentrations may be available.[9]

To provide clinicians with a clear, at-a-glance reference for selecting the appropriate formulation based on the patient's diagnosis, the key prescribing information is summarized in Table 1.

Table 1: Summary of Prescription Formulations, Strengths, and Approved Indications

Formulation	Strength (% w/w)	Common Brand Name(s)	Primary FDA-Approved Indication
Cream	20%	Azelex®, Skinoren®	Mild-to-moderate acne vulgaris
Gel	15%	Finacea®	Inflammatory papules and pustules of mild-to-moderate rosacea
Foam	15%	Finacea® Foam	Inflammatory papules and pustules of mild-to-moderate rosacea

6.2 Dosing Regimens and Application Guidelines

Consistent and correct application is essential for achieving optimal therapeutic outcomes.

• Dosage: For all prescription formulations, the standard dosing regimen is the application of a thin film of the product to the affected areas twice daily, typically in the morning and evening.[5] The medication should be gently but thoroughly massaged into the skin.
• Skin Preparation: Prior to application, the skin should be thoroughly washed with water and a very mild soap or a soapless cleansing lotion, and then patted dry with a soft towel.[5]
• Avoidances: Patients should be counseled to avoid the use of occlusive dressings or wrappings over the treated areas, as this can increase irritation.[5] It is also crucial, particularly for patients with rosacea, to avoid the concomitant use of other potentially irritating topical products. This includes alcoholic cleansers, tinctures, astringents, abrasives, and chemical peeling agents.[19]
• Cosmetics: Cosmetics and makeup may be applied to the face, but only after the Azelaic acid application has fully dried.[19]
• Hand Washing: To prevent inadvertent transfer of the medication to the eyes or mucous membranes, patients should wash their hands with soap and water immediately after application.[19]

7.0 Safety, Tolerability, and Adverse Events

Azelaic acid is widely regarded as a safe and well-tolerated topical medication. Its favorable safety profile is a direct consequence of its minimal systemic absorption, which confines most adverse events to the site of application.

7.1 Common Adverse Reactions

The majority of adverse reactions associated with Azelaic acid are dermatological, mild-to-moderate in severity, and often transient, tending to occur within the first few weeks of initiating therapy and diminishing with continued use.[9]

• Most Frequent: The most commonly reported side effects are sensory in nature. These include burning, stinging, or tingling sensations at the application site. In clinical trials for the 15% gel, this was reported by up to 29% of subjects.[6] Pruritus (itching) is also common, reported by up to 11% of users of the 15% gel.[6]
• Less Frequent: Other common local reactions include scaling, dry skin (xerosis), and erythema (redness) or irritation.[6] Less commonly, contact dermatitis and localized edema may occur.[6]
• Formulation-Dependent Tolerability: The vehicle in which Azelaic acid is formulated plays a significant role in its tolerability. A comparative analysis of clinical trial data, as shown in Table 2, reveals that the 20% cream formulation is associated with a substantially lower incidence of local irritation than the 15% gel, despite its higher concentration of the active ingredient. This suggests that the cream base may be less irritating than the gel base, a critical consideration when selecting a product for patients with sensitive skin.

Table 2: Incidence of Common Adverse Events from Clinical Trials (by Formulation)

Adverse Event	15% Gel (N=457) (%) 24	15% Foam (%) 6	20% Cream (%) 6
Burning/Stinging/Tingling	29%	6.2% (as Pain)	1-5%
Pruritus	11%	2.5%	1-5%
Scaling/Dry Skin/Xerosis	8%	0.7% (as Dryness)	<1% (as Peeling)
Erythema/Irritation	4%	0.7% (as Erythema)	<1%

7.2 Warnings, Precautions, and Contraindications

While generally safe, there are several important warnings and precautions associated with the use of Azelaic acid.

• Contraindication: The only absolute contraindication is a known history of hypersensitivity to Azelaic acid or any of the inactive ingredients in the formulation, such as propylene glycol or benzoic acid.[15]
• Hypopigmentation: Although Azelaic acid's effect on melanocytes is primarily on hyperactive or abnormal cells, isolated cases of hypopigmentation (lightening of the skin) have been reported post-marketing. Therefore, patients with dark complexions (e.g., Fitzpatrick skin types IV-VI) should be monitored for any early signs of changes in skin color.[15]
• Hypersensitivity Reactions: While rare, serious systemic hypersensitivity reactions can occur. Postmarketing reports have included cases of angioedema, eye swelling, facial swelling, dyspnea (shortness of breath), and urticaria (hives). Treatment should be discontinued immediately if such a reaction develops.[24]
• Asthma Exacerbation: There have been rare postmarketing reports of the worsening of asthma, including wheezing and dyspnea, in patients using Azelaic acid. Therefore, caution is advised when prescribing it for patients with a history of asthma.[28]
• Ocular Irritation: Azelaic acid is for dermatologic use only. Contact with the eyes, mouth, and other mucous membranes must be avoided. Accidental ocular exposure can cause significant irritation. In case of contact, the eyes should be flushed with copious amounts of water. If eye irritation persists, medical consultation is advised. Rare cases of iridocyclitis (inflammation of the iris and ciliary body) have been reported following accidental exposure.[15]
• Flammability: The 15% foam formulation contains flammable propellants. Patients must be instructed to avoid fire, flame, and smoking during and immediately following application.[14]

7.3 Use in Special Populations

Azelaic acid has a favorable safety profile for use in specific sensitive populations.

• Pregnancy: It is classified as FDA Pregnancy Category B.[12] This classification is based on animal reproduction studies that showed no evidence of teratogenicity, although embryofetal toxicity was noted at oral doses that were orders of magnitude higher than the maximum recommended human topical dose and were associated with maternal toxicity.[14] Given the minimal systemic absorption (~4%) following topical administration, maternal use is not expected to result in any significant fetal exposure to the drug.[14] Consequently, it is frequently recommended by dermatologists as a safer alternative to topical retinoids (which are contraindicated) for the treatment of acne during pregnancy.[6]
• Lactation: Use of Azelaic acid is considered compatible with breastfeeding.[12] It is unlikely that the drug is absorbed through the skin in clinically relevant amounts that would cause a change in the natural concentration of Azelaic acid in breast milk or result in exposure of the nursing infant to the drug.[14]

8.0 Drug and Other Interactions

The potential for interactions with Azelaic acid is low and primarily limited to local pharmacodynamic effects, as its pharmacokinetic profile precludes clinically significant systemic interactions.

8.1 Pharmacodynamic and Local Interactions

The most clinically relevant interactions are pharmacodynamic in nature, involving the potential for cumulative local skin irritation.

• Topical Irritants: To minimize the risk of excessive dryness, redness, or irritation, the concomitant use of other topical products with known irritant potential should be avoided. Patients using Azelaic acid should be counseled to avoid astringents, abrasive soaps and cleansers, chemical exfoliants (e.g., alpha- and beta-hydroxy acids), and products with high concentrations of alcohol.[19]
• Moderate Interactions with Other Acne Agents: Some drug interaction databases classify the concurrent use of Azelaic acid with other topical acne medications as a "moderate" interaction. This includes agents like topical retinoids (e.g., adapalene, tazarotene, tretinoin), benzoyl peroxide, and salicylic acid.[36] This classification is not based on a pharmacokinetic interaction but on the additive potential for skin irritation. While combination therapy is common in clinical practice, it should be approached with caution, potentially by alternating application times or starting with lower frequencies to assess individual patient tolerability.

8.2 Systemic Drug-Drug Interactions (Pharmacokinetic)

A significant discrepancy exists between theoretical interaction screening databases and clinical prescribing information regarding systemic drug-drug interactions.

• The Database Perspective (Theoretical): Comprehensive pharmacological databases like DrugBank generate extensive lists of potential pharmacokinetic interactions for Azelaic acid.[1] These are typically based on computational models of drug metabolism and excretion. The premise for these listed interactions is that systemically available Azelaic acid might compete with other drugs for renal excretion pathways. For instance, the database suggests that Azelaic acid may decrease the excretion rate of drugs like abacavir or amikacin, potentially leading to higher serum levels, or that a drug like amiloride might increase the excretion rate of Azelaic acid, potentially reducing its efficacy.[1]
• The Clinical & Pharmacological Perspective (Actual): In contrast, multiple clinical resources, including official prescribing information and drug summaries, state that systemic drug-drug interactions are not expected, have not been identified in clinical studies, or are unknown.[14]
• Reconciliation and Expert Analysis: The clinical perspective is the appropriate one for guiding therapeutic decisions. The discrepancy can be resolved by applying fundamental pharmacokinetic principles. The interactions listed in databases are theoretical possibilities that would only be relevant if Azelaic acid achieved significant systemic concentrations. However, as established in Section 4.0, the pharmacokinetic reality of topical application is that only about 4% of the dose is absorbed systemically, and the resulting plasma concentrations do not rise significantly above the normal endogenous range found from dietary sources.[5] For one drug to clinically and significantly inhibit the renal excretion of another, it must achieve a sufficient concentration at the renal tubules to saturate or competitively inhibit the relevant transporters. The negligible increase in systemic Azelaic acid concentration following standard topical use makes it pharmacologically implausible that it could reach the necessary threshold to cause these theoretical interactions. Therefore, while the database warnings are algorithmically generated, they lack clinical relevance for the approved topical route of administration and can be safely disregarded in routine practice.

8.3 Food and Lifestyle Interactions

While there are no direct food-drug interactions, certain dietary and lifestyle choices are relevant for patients using Azelaic acid for specific conditions.

• Relevance to Rosacea: For patients being treated for rosacea, successful management often involves both pharmacological therapy and trigger avoidance. Patients are therefore advised to avoid known triggers that can provoke cutaneous vasodilation, leading to erythema, flushing, and blushing. Common triggers include alcoholic beverages, spicy foods, and thermally hot drinks such as hot coffee and tea.[19] This is not an interaction with the drug itself but rather a complementary lifestyle modification to manage the underlying condition.
• Relevance to Acne: This dietary and lifestyle advice is generally not necessary for patients using Azelaic acid solely for the treatment of acne vulgaris, unless they have a known individual dietary trigger for their acne.[19]

9.0 Global Regulatory Status and Commercial Landscape

A uniquely compelling aspect of Azelaic acid is the dramatic divergence in its regulatory classification across major international markets. This has profound implications for patient access, clinical practice, commercialization, and public health policy, reflecting different philosophical approaches to balancing efficacy, safety, and the role of healthcare professionals in managing common skin conditions.

9.1 United States (FDA)

In the United States, the Food and Drug Administration (FDA) strictly regulates Azelaic acid as a prescription-only medicine, requiring consultation with and a prescription from a licensed healthcare provider.[26]

• Regulatory Status: Prescription Only (Rx).
• Approval History: The regulatory history of Azelaic acid in the US reveals an evolution in FDA requirements and standards for topical dermatological drugs.
• 1995: The first approval was granted for Azelex® (20% cream), manufactured by Allergan, for the topical treatment of mild-to-moderate inflammatory acne vulgaris.[6] At the time, long-term animal carcinogenicity testing was not deemed necessary, as Azelaic acid was considered a human dietary component with a simple structure not suggestive of carcinogenic potential.[34]
• 2002: A new dosage form, Finacea® (15% gel) from Bayer HealthCare, was approved for the topical treatment of inflammatory papules and pustules of mild-to-moderate rosacea.[12]
• 2015: A third formulation, Finacea® (15% foam), also from Bayer, was approved for the same rosacea indication.[21] Reflecting a significant shift in regulatory expectations over the two decades since the initial approval, the approval for the foam formulation came with a postmarketing requirement for the sponsor to conduct a 104-week dermal carcinogenicity study in mice.[34] This demonstrates a raising of the safety bar for new approvals, even for well-established molecules.
• Generic Availability: The patents for the original branded products have expired, leading to the introduction of generic formulations. Generic versions of the 15% Azelaic acid gel, for example, received ANDA (Abbreviated New Drug Application) approval and became available in the US market around November 2018.[41]

9.2 Australia (TGA)

Australia's Therapeutic Goods Administration (TGA) has adopted a tiered, intermediate approach to the regulation of Azelaic acid, distinguishing between concentrations and requiring pharmacist involvement for consumer access.

• Current Status: Azelaic acid is a scheduled medicine under the Poisons Standard. It is listed in Schedule 2 (Pharmacy Medicine), which requires advice from a pharmacist and is sold behind the counter, and Schedule 4 (Prescription Only Medicine), which requires a doctor's prescription.[43]
• Upcoming Changes (Effective October 1, 2024): The TGA has made a final decision to amend the Poisons Standard. A new entry in Schedule 5 will be created for cosmetic and therapeutic preparations containing 10% or less of Azelaic acid.[43] Schedule 5 substances pose a low-to-moderate risk and require cautionary labeling but can be sold in a wider range of retail environments without direct pharmacist supervision. However, these products will require specific safety labeling, such as "avoid contact with skin," reflecting ongoing concerns about potential irritation.[43] This decision follows an earlier interim decision in 2020 that had rejected a proposal to completely unschedule low-concentration products due to concerns about consumers potentially self-diagnosing and inappropriately managing more serious dermatological conditions that might mimic acne or rosacea.[44] This new tiered system represents a nuanced approach, expanding access while retaining some regulatory control.

9.3 European Union (EMA)

The regulatory approach in the European Union stands in stark contrast to that of the United States.

• Regulatory Status: In the EU, Azelaic acid is primarily regulated as a cosmetic ingredient. According to EU Commission Regulation 1223/2009, it can be used in personal care and cosmetic products without any concentration restrictions.[40]
• Implications: This classification has created a vastly different market landscape. It allows for the widespread availability of high-strength (e.g., 10%, 15%) Azelaic acid serums, creams, and lotions directly to consumers over-the-counter and via online retailers from a multitude of cosmetic and "cosmeceutical" brands.[46] While pharmaceutical versions like Finacea® and Skinoren® are also available, they are often sold over-the-counter without a prescription in many member states, including Italy, Portugal, Poland, and Greece.[47] This regulatory philosophy prioritizes consumer access to an effective and safe ingredient, placing more responsibility on the consumer and the manufacturer for appropriate use.

The significant global divergence in regulatory philosophy is summarized for direct comparison in Table 3.

Table 3: Comparison of Regulatory Status in the US, EU, and Australia

Region/Authority	Regulatory Classification	Typical Availability	Key Formulations/Strengths
United States (FDA)	Prescription Only Medicine (Rx)	By prescription from a licensed healthcare provider only.	15% Gel/Foam, 20% Cream
European Union (EU Commission)	Unrestricted Cosmetic Ingredient	Over-the-counter (OTC) in pharmacies, retail stores, and online.	Pharmaceutical (15%, 20%) and cosmetic (≤15%) formulations widely available OTC.
Australia (TGA)	Tiered: Schedule 4 (Prescription), Schedule 2 (Pharmacy Medicine), Schedule 5 (Caution - effective Oct 2024)	Prescription-only or via consultation with a pharmacist. Low-strength versions to be more widely available with cautionary labeling.	20% cream (S2/S4), 15% gel (S4). ≤10% formulations to be S5.

9.4 International Brand Landscape

The varied regulatory environment has led to a diverse and rich global market for Azelaic acid products.

• Major Pharmaceutical Brands: The globally recognized pharmaceutical brands are Finacea®, Skinoren®, and Azelex®.[7]
• Regional Brands: A vast number of local and regional pharmaceutical brands exist. Examples include Cutacelan® in Argentina and Mexico; Azclear® in Australia; Acmed® in Germany and Greece; Hascoderm® and Acne-Derm® in Poland; and Zeliderm® and Zelaika® in Spain.[9]
• Cosmeceutical Brands: The permissive regulatory environment in the EU and other regions has fueled the growth of popular cosmeceutical brands offering high-strength Azelaic acid. Prominent examples include The Ordinary, The INKEY List, Facetheory, Theramid, Isispharma, and Laboratoire ACM.[9]

10.0 Conclusion and Future Perspectives

Azelaic acid stands as a paragon of a modern dermatological therapeutic agent, distinguished by its remarkable versatility, robust efficacy, and an exceptionally high margin of safety. This monograph has detailed the extensive evidence supporting its role in clinical practice. Its status as a naturally occurring dicarboxylic acid, familiar to human metabolic pathways, provides a strong biological foundation for its excellent tolerability.

The clinical value of Azelaic acid is derived from its unique pleiotropic mechanism of action. It is not a "magic bullet" with a single target, but rather a sophisticated modulating agent that concurrently addresses the principal pathophysiological drivers of multiple skin diseases. Its ability to simultaneously exert anti-infective, anti-inflammatory, anti-keratinizing, and anti-melanogenic effects explains its established efficacy as a cornerstone therapy for both acne vulgaris and rosacea, and justifies its expanding and evidence-based off-label use for challenging hyperpigmentary disorders like melasma and post-inflammatory hyperpigmentation.

Furthermore, its pharmacokinetic profile is nearly ideal for a topical drug. The creation of a "topical reservoir" through slow, rate-limiting percutaneous absorption maximizes its local concentration and duration of action at the target site, while the minimal systemic bioavailability precludes clinically significant systemic adverse events and drug-drug interactions. This combination of local potency and systemic safety, along with its favorable profile for use during pregnancy and lactation, solidifies its position as a first-line or essential alternative therapy in numerous clinical scenarios.

The fascinating global divergence in its regulatory status—from a strictly controlled prescription drug in the United States to an unrestricted cosmetic ingredient in the European Union—highlights differing public health philosophies and will continue to shape its accessibility and market dynamics.

Looking to the future, several avenues for development exist. The continued exploration of novel delivery systems, building upon existing liposomal technology, may further enhance its penetration, efficacy, and tolerability, potentially allowing for lower concentrations or once-daily dosing. There is also a clear need for more robust, large-scale, randomized controlled trials to formally investigate its efficacy in its current off-label uses. Such studies could provide the high-quality evidence required by regulatory bodies like the FDA to grant expanded approved indications, particularly for post-inflammatory hyperpigmentation and melasma, thereby formalizing what is already a widespread and successful clinical practice. In summary, Azelaic acid is a fundamentally important molecule in dermatology, and its clinical journey is a testament to the value of understanding and leveraging pleiotropic pharmacological activity.

Works cited

1. Azelaic acid: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 1, 2025, https://go.drugbank.com/drugs/DB00548
2. Azelaic Acid | C9H16O4 | CID 2266 - PubChem, accessed October 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Azelaic-Acid
3. azelaic acid - Inventory of Food Contact Substances Listed in 21 CFR - FDA, accessed October 1, 2025, https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=IndirectAdditives&id=AZELAICACID
4. azelaic acid, 123-99-9 - The Good Scents Company, accessed October 1, 2025, http://www.thegoodscentscompany.com/data/rw1220821.html
5. AZELEX® (azelaic acid cream) 20% For Dermatologic Use Only Not for Ophthalmic Use - accessdata.fda.gov, accessed October 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020428Orig1s027lbl.pdf
6. Azelaic Acid Therapeutic Cheat Sheet - Next Steps in Dermatology, accessed October 1, 2025, https://nextstepsinderm.com/derm-topics/azelaic-acid-therapeutic-cheat-sheet/
7. Azelaic acid - brand name list from Drugs.com, accessed October 1, 2025, https://www.drugs.com/ingredient/azelaic-acid.html
8. The multiple uses of azelaic acid in dermatology: mechanism of action, preparations, and potential therapeutic applications - Termedia, accessed October 1, 2025, https://www.termedia.pl/The-multiple-uses-of-azelaic-acid-in-dermatology-mechanism-of-action-preparations-and-potential-therapeutic-applications,7,52122,1,1.html
9. The multiple uses of azelaic acid in dermatology: mechanism of action, preparations, and potential therapeutic applications - PubMed Central, accessed October 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10809820/
10. Azelaic Acid | Drug Lookup | Pediatric Care Online | American ..., accessed October 1, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5204/Azelaic-Acid
11. Oil-free Antibacterial Lotion - Azclear, accessed October 1, 2025, https://www.azclearskin.com/au/en/products/azclear-action-medicated-lotion.html
12. Azelaic Acid: Evidence-based Update on Mechanism of Action and ..., accessed October 1, 2025, https://jddonline.com/articles/azelaic-acid-evidence-based-update-on-mechanism-of-action-and-clinical-application-S1545961615P0964X/
13. What is the mechanism of Azelaic Acid? - Patsnap Synapse, accessed October 1, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-azelaic-acid
14. Azelex - Drug Summary, accessed October 1, 2025, https://www.pdr.net/drug-summary/Azelex-azelaic-acid-1111
15. Azelex, Finacea (azelaic acid) dosing, indications, interactions, adverse effects, and more., accessed October 1, 2025, https://reference.medscape.com/drug/azelex-finacea-azelaic-acid-343463
16. Azelaic Acid (Finacea, Azelex) Side Effects, Uses & Dosage - MedicineNet, accessed October 1, 2025, https://www.medicinenet.com/azelaic_acid_gel-topical/article.htm
17. Showing BioInteractions for Azelaic acid (DB00548) | DrugBank Online, accessed October 1, 2025, https://go.drugbank.com/drugs/DB00548/biointeractions
18. Azelaic Acid-Biochemistry and Metabolism, accessed October 1, 2025, https://medicaljournalssweden.se/actadv/article/download/4744/7209
19. Azelaic Acid Topical : MedlinePlus Drug Information, accessed October 1, 2025, https://medlineplus.gov/druginfo/meds/a603020.html
20. Azelaic acid (topical route) - Side effects & dosage - Mayo Clinic, accessed October 1, 2025, https://www.mayoclinic.org/drugs-supplements/azelaic-acid-topical-route/description/drg-20062084
21. Finacia Foam (Azelaic Acid) the Newest Topical Treatment FDA ..., accessed October 1, 2025, https://www.ahdbonline.com/issues/2016/march-2016-vol-9-seventh-annual-payers-guide/finacia-foam-azelaic-acid-the-newest-topical-treatment-fda-approved-for-the-treatment-of-inflammatory-lesions-of-rosacea
22. A Comprehensive Review of Azelaic Acid Pharmacological Properties, Clinical Applications, and Innovative Topical Formulations - PMC - PubMed Central, accessed October 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12472904/
23. Azelaic acid Completed Phase 3 Trials for Rosacea Treatment | DrugBank Online, accessed October 1, 2025, https://go.drugbank.com/drugs/DB00548/clinical_trials?conditions=DBCOND0019774&phase=3&purpose=treatment&status=completed
24. AZELAIC ACID gel - DailyMed, accessed October 1, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66298d50-d4e2-4852-bbab-581389c488cb
25. Azelaic Acid Gel 15% in the Management of Papulopustular Rosacea: A Status Report on Available Efficacy Data and Clinical Application - PubMed, accessed October 1, 2025, https://pubmed.ncbi.nlm.nih.gov/21916272/
26. Clinical Policy: Azelaic Acid (Finacea Topical Gel/Foam) - Ambetter Health, accessed October 1, 2025, https://www.ambetterhealth.com/content/dam/centene/Superior/policies/pharmacy-policies/HIM.PA.119.pdf
27. Ingredient Deep Dive: Azelaic Acid – The Dose - Skin + Me, accessed October 1, 2025, https://www.skinandme.com/the-dose/ingredient-deep-dive-azelaic-acid/
28. Azelaic Acid: Benefits and Dangers of This Ingredient. - Typology, accessed October 1, 2025, https://us.typology.com/library/what-are-the-dangers-of-azelaic-acid
29. Azelaic Acid: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed October 1, 2025, https://www.rxlist.com/azelaic_acid/generic-drug.htm
30. Azelaic acid gel: Dosage, side effects, uses, cost, and more - MedicalNewsToday, accessed October 1, 2025, https://www.medicalnewstoday.com/articles/drugs-azaleic-acid
31. Azelaic Acid: Acne Uses, Side Effects, Dosage - MedicineNet, accessed October 1, 2025, https://www.medicinenet.com/azelaic_acid/article.htm
32. Azelaic Acid Topical Gel - accessdata.fda.gov, accessed October 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021470.pdf
33. Azelaic Acid Gel - Rosacea Treatment - Cleveland Clinic, accessed October 1, 2025, https://my.clevelandclinic.org/health/drugs/18644-azelaic-acid-gel
34. A Review Of The Regulatory History Of Azelaic Acid And The Changing Requirements At FDA | Premier Consulting, accessed October 1, 2025, https://premierconsulting.com/resources/blog/changing-face-a-review-of-the-regulatory-history-of-azelaic-acid-and-the-changing-requirements-at-fda/
35. Azelaic acid topical Uses, Side Effects & Warnings - Drugs.com, accessed October 1, 2025, https://www.drugs.com/mtm/azelaic-acid-topical.html
36. Azelex Interactions Checker - Drugs.com, accessed October 1, 2025, https://www.drugs.com/drug-interactions/azelaic-acid-topical,azelex.html
37. Azelaic acid topical Interactions - Drugs.com, accessed October 1, 2025, https://www.drugs.com/drug-interactions/azelaic-acid-topical.html
38. azelaic acid 15 % topical gel - Kaiser Permanente, accessed October 1, 2025, https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.azelaic-acid-15-topical-gel.448746
39. azelaic acid - Drug Central, accessed October 1, 2025, https://drugcentral.org/drugcard/270
40. FAQ - Azeco Cosmeceuticals, accessed October 1, 2025, https://azeco-cosmeceuticals.com/faq/
41. Azelaic acid - PharmaKB, accessed October 1, 2025, https://www.pharmakb.com/drug-report/azelaic20acid
42. Glenmark Pharmaceuticals receives ANDA approval for Azelaic Acid Gel, 15%, accessed October 1, 2025, https://glenmarkpharma-us.com/press/glenmark-pharmaceuticals-receives-anda-approval-for-azelaic-acid-gel-15/
43. Azelaic Acid...A Multifunctional Ingredient in Skincare Formulations ..., accessed October 1, 2025, https://www.phfactor.com.au/azelaic-acid-a-multifunctional-ingredient-in-skincare-formulations/
44. 4.1 Azelaic acid | Therapeutic Goods Administration (TGA), accessed October 1, 2025, https://www.tga.gov.au/resources/publication/scheduling-decisions-interim/notice-interim-decisions-proposed-amendments-poisons-standard-acms-accs-and-joint-acms-accs-meetings-november-2020/41-azelaic-acid
45. ANTI ACNE - Azelaic, accessed October 1, 2025, https://azelaic.com/applications/anti-acne/anti-acne/
46. The INKEY List EU Azelaic Acid 10% for Redness Relief, accessed October 1, 2025, https://eu.theinkeylist.com/products/redness-relief-solution
47. In which European countries can you buy 15 0r 20 % azelaic acid OTC? - Reddit, accessed October 1, 2025, https://www.reddit.com/r/EuroSkincare/comments/psk187/in_which_european_countries_can_you_buy_15_0r_20/
48. where in Europe can I buy high concentration azelaic acid without prescription? - Reddit, accessed October 1, 2025, https://www.reddit.com/r/EuroSkincare/comments/1h6cdlu/where_in_europe_can_i_buy_high_concentration/
49. Finacea Gel 15% Acido azelaico Rosacea 30g - xFarma.it, accessed October 1, 2025, https://www.xfarma.it/en/finacea-gel-30g-15.html